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Abstract 
 
The history of clinical research accounts for the high ethical, scientific, and regulatory standards 
represented in current practice. In this review, we aim to describe the advances that grew from 
failures and provide a comprehensive view of how the current gold standard of clinical practice 
was born. This discussion of the evolution of clinical trials considers the length of time and 
efforts that were made in order to designate the primary objective, which is providing improved 
care for our patients. A gradual, historic progression of scientific methods such as comparison of 
interventions, randomization, blinding, and placebos in clinical trials demonstrates how these 
techniques are collectively responsible for a continuous advancement of clinical care. 
Developments over the years have been ethical as well as clinical. The Belmont Report, which 
many investigators lack appreciation for due to time constraints, represents the pinnacle of 
ethical standards and was developed due to significant misconduct. Understanding the history of 
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In modern medicine, the clinical trial is the gold standard and most dominant form of clinical 
research. Clinical trials are well controlled and function under a strict regulatory environment. 
While it can be frustrating for new investigators to appreciate the necessary complexities of 
clinical research, recognizing that the process by which we conduct clinical trials has been 
evolving since the earliest days of medicine can be helpful. Some version of a controlled trial has 
existed for thousands of years.1 The first recorded manifestations of clinical trials were a variety 
of attempts to compare interventions. Clinical trials later included the incorporation of 
randomization, blinding, and placebos in studies with a relatively recent focus on ethic conduct 
of human research. Regardless of the failures and tribulations that materialized in its evolution, 
the history of clinical trials and the lessons learned as a result lead to a higher quality of research 
and better care for our patients. In this review, we will consider the advancement of clinical trials 
from a historical perspective to better understand the foundation and intent of conducting 
research for the primary benefit of the patient. As will be discussed, the history of clinical 
research is marked by scientific, ethical, and regulatory challenges.2 
 
According to the International Committee of Medical Journal Editors, clinical research is defined 
as “any research project that prospectively assigns human subjects to intervention and 
comparison groups to study the cause-and-effect relationship between a medical intervention and 
health outcome”.1 The first documented evidence of a clinical trial fitting this definition was 
outlined in the Book of Daniel from the Old Testament around 500 BC in which a nutritional 
experiment utilized a control group. Daniel and three of his brothers were assigned to a diet of 
only vegetables and water and were compared with the men complying with the king’s diet of 
meat and wine. Daniel and his brothers were noticeably healthier, thus the diet of the king’s men 
was altered.3 Although the accuracy of this account cannot be confirmed, the idea of conducting 
an intervention-based trial using a concurrent control group was clearly demonstrated.   
 
In 1537, Ambroise Paré conducted an unintentional trial, now commonly noted as the first 
clinical trial in history. Paré was a French military surgeon who developed a novel therapy for 
battlefield wounds when the standard supplies for treatment, boiling oil, ran out.4 Alternatively, 
Paré applied a digestive mixture of turpentine, egg yolk, and oil of roses for the sealing of 
soldiers’ wounds that did not receive the boiling oil. Despite Paré’s apprehensions that these 
soldiers would die from lack of cauterization, he found they were in little pain, their wounds 
were minimally swollen and irritated, and were overall in better condition than the soldiers who 
had received the hot oil.4 Although unplanned, Paré’s innovation provided a method much more 
effective than the standard treatment. Thus, we begin to encounter the idea of advancement of 
care through experimentation. 
 
Many physicians throughout history struggled with limited standard of care options. In the 17th 
century, Jan Baptist van Helmont endeavored to ensure that comparisons of treatments were 
being made. Namely, he called attention to and rejected the traditional therapy of bloodletting 
and purging for fevers.5 Van Helmont argued that practitioners have a responsibility to recognize 
treatments that are likely to help their patients while causing minimal harm. He questioned the 
traditional therapies of humoral imbalance and a “fair therapeutic contest” instead suggesting 
therapies that considered the type and cause of disease. 5 
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It was roughly one hundred years after Van Helmont’s proposal that the first recorded planned 
clinical trial was conducted by Dr. James Lind, a Scottish naval surgeon.4 In 1747, Lind began to 
study scurvy, which killed thousands of British sailors annually. Lind prepared for his 
experiment by conducting a systematic review of what had been written previously on the 
treatment of scurvy, from which he extracted six proposed treatments. Outlined in his book, A 
Treatise of the Scurvy, Lind reports that he added to his first-hand experience by evaluating 
reports of the disease and reports sent to him by members of the Society of Naval Services.6  
 
The comparative trial included 12 sailors affected by scurvy that were lodged together, separated 
from the rest of the crew, and held on a common diet. The trial compared treatments of scurvy 
including cider, an elixir of vitriol, vinegar, seawater, citrus, or nutmeg. The citrus diet, which 
composed of oranges and lemons, proved to be a far more effective treatment than the other five. 
The two sailors treated with citrus received two oranges and one lemon every day, for six days. 
The rest of the sailors were treated for two weeks, but after half the time, the men receiving 
citrus were well enough to return to work. One of these sailors was even appointed nurse to the 
rest of the sick. The two sailors treated with cider were ordered each a quart of cider a day and 
Lind found that “Next to the oranges, I thought the cider had the best benefits”.7 Although not 
comparable to the condition of the citrus group, the men given cider had improved weakness and 
gums. The mouths of those who used the elixir of vitriol were clearer and in better condition, 
although Lind expressed that he had doubted the efficacy of this treatment, as it alleviated no 
other symptoms. No remarkable change in condition was noted for those who took seawater, 
vinegar, or nutmeg. Despite the clear results of his trials, the implementation of citrus as a part of 
the British Naval diet did not take place until fifty years later due to cost concerns.2 
 
The case of scurvy illustrates the motivation and economic basis for judgment during the 18th 
century. The clear research evidence collected by Lind made little influence on policy and 
practice due to the high price and low availability of citrus fruits. Being aware of this, Lind left 
his readers confused about his recommendations in A Treatise of the Scurvy because of his 
alliance and duty to the British Navy. Although cases as extensive as Lind’s are not as 
widespread today, economic realities remain a part of healthcare.   
 
Following the enactment and publication of Lind’s work, an increasing number of comparative 
studies took place. Societal challenges were answered using scientific reasoning and 
methodology to provide necessary advancement to the public.1 In 1865, a French physiologist 
Claude Bernard published the book Introduction to the Study of Experimental Medicine. 
Bernard’s mission was to challenge the thinking of medical professionals and urge them to 
consider applying scientific principles to their standards of care. A desire for knowledge and 
investigation of cause and effect were included in Bernard’s account of what makes a substantial 
scientific theory. Bernard wrote, “To learn we must necessarily reason about what we have 
observed, compare the facts, and judge them by other facts as controls”.8 His aim to establish the 
scientific method in medicine ultimately became a cornerstone in modern clinical trial operations 
based on sound scientific principles. 
 
Around this time, we start to see new elements introduced into clinical trials that not only follow 
sound scientific methods, but also improve the validity of trial data. The early history of clinical 
trials exhibits efforts of controlling trials by using comparative groups and utilizing the scientific 
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method. Following Lind’s efforts, systematic and precise approach revealed a more sophisticated 
clinical trials mechanism.  
 
The arrival of the placebo marked an important breakthrough in the history of clinical research. 
In 1863, Austin Flint conducted a trial involving patients with rheumatic fever, and compared the 
results of the active treatment with that of a placebo.9 Flint discovered that there was no 
difference in the natural history of the disease, indicating that the symptoms associated with 
rheumatic fever subsided naturally over time, not as a result of the orthodox drug treatment. The 
implementation of a placebo marked a shift in medicine in which identifying the positive benefits 
of active drug treatments were centralized in importance.  
 
Patulin, an extract of Penicillium patulinum, was investigated as a treatment for the common 
cold.2 The patulin trial was the first double blind comparative trial, conducted by the Medical 
Research Council (MRC) of the United Kingdom from 1943-1944. The MRC’s call for 
investigation and a large multi-center study was sparked by a 1943 report in the Sunday Express 
that claimed a MRC spokesperson found results of a preliminary patulin trial that suggested a 
cure for the common cold was quickly approaching.10 The Ministry of Supply, believing the 
report to be true, informed the MRC that they were expected to provide the raw material for 
manufacturing of the drug. To provide clarity to the muddled results available, a preliminary 
formal controlled clinical trial was conducted within the Royal Navy. These results suggested 
that patulin was very unlikely to be a cure, but the Council was willing to conduct a trial on a 
larger scale.11 The trial was conducted in widely distributed areas of Great Britain. Extensive 
efforts were made to ensure double blinding of the medical personnel and patients. A conclusion 
of the trial data showed that success of treatment was no different between the control and 
patulin treatment groups.  
 
Although the data did not prove any positive effects of patulin in treatment for the common cold, 
the efforts were exemplary in involving researchers, funders, manufacturers, patients, and 
government working towards a common motive to examine a medical issue.10 The chief medical 
officer at one of the trial sites noted, “It is to be regretted that the work had not produced more 
helpful results but I do agree that negative results of this kind are very important and I only will 
they were more often published since I am sure that a lot of research work is done because other 
people have not thought it worthwhile to publish their results”.11 Their use of double blinding 
served as a model for subsequent clinical trials.  
 
The popularization of randomization in clinical trials was marked by the tests of streptomycin for 
the treatment of tuberculosis. In 1946, Austin Bradford Hill and Philip Hart were assigned by the 
MRC to conduct tests of the promising antibiotic, but had an extreme shortage of the drug.12 To 
manage their limited supply of streptomycin, participants were randomly assigned to control 
groups and treatment groups. Randomization eradicated the frequently observed bias in which 
clinicians will place healthier patients in the experimental group and sicker patients in the control 
group. It not only achieves similarity between groups, but it provides protection against bias. The 
results of Hill and Hart’s study began the virtually universal use of randomization in clinical 
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Over several hundred years the scientific aspects of conducting clinical trials and the associated 
medical advances continued to improve at a seemingly exponential rate, especially in the early 
1900’s. The regrettable experiments that took place in the 1930’s and 40’s that put science over 
humanity proved that a greater focus on the ethics of clinical trials was necessary.  
 
The Nuremberg Code was introduced in 1947 following the infamous Nuremberg trials in 
Germany in which Nazi physicians were tried for crimes committed during human experiments 
on concentration camp prisoners.13 Nazi physicians took advantage of prisoners by subjecting 
them to nonconsensual medical experiments. For example, Dr. Horst Schumann led sterilization 
experiments at Auschwitz in an attempt to eliminate the Jewish race. Male and female prisoners 
were irradiated with X-rays and given injections and suffered serious side effects, which were 
left untreated.14 In the Nuremberg trials, accounts of pharmaceutical testing, war-injury 
simulation, and other cruelties were accounted, of which many Nazi physicians were proud.  
 
Also known as the International Code of Medical Ethics, the Nuremberg Code outlined the first 
basic elements of research ethics, criteria that was widely accepted but was formulated to judge 
those physicians who had committed despicable crimes against humanity during World War II.14 
The original ten essential conditions of experiment requirements demonstrated protection of 
human participants in clinical trials. The document specified that voluntary consent was essential 
and that the benefits of research must outweigh the risks. Although the Nuremberg Code was 
highly publicized and a clear instruction for investigator’s responsibilities, the subsequent two 
decades were not absent of unethical research. The Nuremberg Code had succeeded in 
solidifying a predominant acceptance of ethical research, but there continued to be violations by 
some investigators.15 
 
The hallmark of unethical research practices is the Tuskegee syphilis study, which began in 1932 
and continued for forty years without any regard to the standards established at Nuremberg.16 
The study was titled “Tuskegee Study of Untreated Syphilis in the Negro Male”, and was 
initiated when there were no known treatments for the disease. Researchers withheld treatment 
from the participants when, in 1947, penicillin became the standard treatment for syphilis. 
Patients were exploited for their vulnerability, coerced by offers of free medical care and health 
insurance, and researchers used extreme levels of deception by telling participants they were to 
be treated for “bad blood”. The blatant disregard for humanity in the name of science 
consequently led to deaths and infections of participants’ partners and children.  The Tuskegee 
study exemplifies the necessity of providing protections for research subjects and is a reminder 
of the fact that humanity must be put above science.17   
 
In 1964, the World Medical Association drafted an international manuscript promoting voluntary 
involvement and informed consent in human subjects research called the Declaration of Helsinki. 
It has since been regularly revised and encompasses international research ethics and delineates 
rules for “research combined with medical care” and “non-therapeutic research”.18 Although not 
legally binding, the Declaration of Helsinki serves as the basis for laws that govern medical 
research in countries across the world. In the United States, the Belmont Report further solidified 
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Prepared in 1979 by the National Commission for the Protection of Human Subjects in 
Biomedical and Behavioral Research (19), the Belmont Report outlined basic ethical principles 
and guidelines for conducting research with human participants. Three basic principles 
encompass these standards: respect for persons, beneficence, and justice.18 Each principle covers 
several applications and serves as the foundation for guidelines concerning human participants in 
clinical experiments.  
 
Clinical research evolved from trial-by-error to current customs of strict and comprehensive 
regulations. Scientific challenges were conquered through the implementation of experimental 
controls, randomization, therapy comparison, placebo, and double-blind experimentation. Ethical 
and regulatory advances progressed by establishing a framework of standards through the 
Nuremberg Code, Helsinki Declaration, and the Belmont Report. The advancements made to 
clinical trials throughout history have laid the foundation for ethically and scientifically sound 
research.  
 
The 20th century was clearly marked by drastic changes in medical practice with new methods of 
examining experimental designs being implemented throughout the century. The emergence of 
evidence-based practice was followed by the need for standardized procedures for assessing 
efficacy of therapies and guidelines for protecting the patients involved. Clinical research is 
necessary to provide the best possible care to current patients20 and advance available therapies, 
but clinical trials must continue to evolve. History has proven that standardized clinical trials 
answer questions other approaches of scientific investigation cannot.21 Modern challenges, 
including big data, pharmaceutical and device companies designing trials for marketing, 
monetary considerations, time constraints, and expanding public health data present new 
challenges and opportunities for clinical research, but require continuous improvement of 
research methods to assure the best possible clinical outcomes. The advanced ability to obtain 
and manipulate data will especially challenge privacy concerns and respect for persons. As we 
progress into a new era of clinical research, it is critical that investigators remember the long and 
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